Superior performance to laboratory test and alternative available point of care platforms
Genedrive (AIM:GDR) shares fall 10% following CEO departure
Genedrive PLC (AIM: GDR) shares dropped 10% after the announcement that CEO James Cheek has left the company by mutual agreement.
Genedrive PLC (AIM: GDR) NICE recommends CYP2C19-ID Kit in final guidance
NICE recommends the Genedrive® CYP2C19-ID Kit in final guidance Genedrive® CYP2C19-ID test chosen as the preferred platform for point-of-care genotype testing prior to clopidogrel treatment for stroke patients in the
Genedrive PLC (AIM:GDR) Breakthrough Device Designation from the U.S. FDA
genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) for the Genedrive® MT-RNR1
Genedrive PLC (AIM:GDR) Initial orders of the Genedrive MT-RNR1 Products
Initial orders of the Genedrive MT-RNR1 Products for new sites in the UK
Genedrive PLC (AIM:GDR) Proposed REX Retail Offer
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces its intention to raise funds by means of a proposed retail offer via the Retail Capital Markets ‘REX’ portal (the
Genedrive PLC (AIM:GDR) NICE recommends the Genedrive CYP2C19-ID Kit
NICE recommends the Genedrive® CYP2C19-ID Kit
Genedrive PLC (AIM:GDR) Initial overseas orders of MT-RNR1 ID kit
Initial overseas orders of the Genedrive® MT-RNR1 ID Kit
Genedrive PLC (AIM:GDR) Multi-partner grant awarded
Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Genedrive PLC – NICE recommends CYP2C19 genotyping
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
Genedrive PLC (AIM:GDR) Commence of roll out in Greater Manchester
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
Genedrive PLC (AIM:GDR) AIHL test preliminary recommendation by NICE
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System